Mainstream Capital Management LLC Purchases 668 Shares of Eli Lilly and Company $LLY

Mainstream Capital Management LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 41.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,298 shares of the company’s stock after purchasing an additional 668 shares during the quarter. Eli Lilly and Company comprises about 1.3% of Mainstream Capital Management LLC’s portfolio, making the stock its 20th biggest position. Mainstream Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,791,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the 1st quarter valued at about $27,000. Citizens National Bank Trust Department raised its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $939.61.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $747.29 on Wednesday. The stock has a 50-day moving average of $736.98 and a two-hundred day moving average of $768.86. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.30. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $707.27 billion, a P/E ratio of 48.84, a P/E/G ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.